1. Home
  2. PGEN vs ZVRA Comparison

PGEN vs ZVRA Comparison

Compare PGEN & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGEN
  • ZVRA
  • Stock Information
  • Founded
  • PGEN 1998
  • ZVRA 2006
  • Country
  • PGEN United States
  • ZVRA United States
  • Employees
  • PGEN N/A
  • ZVRA N/A
  • Industry
  • PGEN Biotechnology: Pharmaceutical Preparations
  • ZVRA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PGEN Health Care
  • ZVRA Health Care
  • Exchange
  • PGEN Nasdaq
  • ZVRA Nasdaq
  • Market Cap
  • PGEN 475.2M
  • ZVRA 481.7M
  • IPO Year
  • PGEN N/A
  • ZVRA 2015
  • Fundamental
  • Price
  • PGEN $1.85
  • ZVRA $12.34
  • Analyst Decision
  • PGEN Strong Buy
  • ZVRA Strong Buy
  • Analyst Count
  • PGEN 3
  • ZVRA 9
  • Target Price
  • PGEN $6.00
  • ZVRA $23.25
  • AVG Volume (30 Days)
  • PGEN 2.2M
  • ZVRA 1.0M
  • Earning Date
  • PGEN 08-13-2025
  • ZVRA 08-12-2025
  • Dividend Yield
  • PGEN N/A
  • ZVRA N/A
  • EPS Growth
  • PGEN N/A
  • ZVRA N/A
  • EPS
  • PGEN N/A
  • ZVRA N/A
  • Revenue
  • PGEN $4,201,000.00
  • ZVRA $40,588,000.00
  • Revenue This Year
  • PGEN $158.57
  • ZVRA $292.31
  • Revenue Next Year
  • PGEN $1,086.91
  • ZVRA $78.65
  • P/E Ratio
  • PGEN N/A
  • ZVRA N/A
  • Revenue Growth
  • PGEN N/A
  • ZVRA 46.47
  • 52 Week Low
  • PGEN $0.65
  • ZVRA $5.45
  • 52 Week High
  • PGEN $2.17
  • ZVRA $12.55
  • Technical
  • Relative Strength Index (RSI)
  • PGEN 68.77
  • ZVRA 84.06
  • Support Level
  • PGEN $1.56
  • ZVRA $8.58
  • Resistance Level
  • PGEN $2.04
  • ZVRA $12.37
  • Average True Range (ATR)
  • PGEN 0.11
  • ZVRA 0.51
  • MACD
  • PGEN 0.04
  • ZVRA 0.31
  • Stochastic Oscillator
  • PGEN 70.00
  • ZVRA 98.47

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Share on Social Networks: